Unstacking the deck in follicular lymphoma clinical trials

Affiliations

¹ Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, NY, United States.
² Perlmutter Cancer Center, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, United States.

Comment

Samuel Yamshon et al. J Natl Cancer Inst. 2025.

. 2025 Nov 1;117(11):2154-2155.

doi: 10.1093/jnci/djaf231.

¹ Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, NY, United States.
² Perlmutter Cancer Center, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, United States.

No abstract available

Comment on

Meeting trial eligibility in Follicular lymphoma patients is associated with overall survival but not progression-free survival.
Wong KSQ, Martynchyk A, Krisnadi Z, Swain F, Zargari A, Cassidy L, Mills G, Lim K, Gervasi J, Smallbone P, Wang J, Slifirski O, Loh Z, Cheah C, Keane C, Gregory G, Lasica M, Chong G, Barraclough A, Cochrane T, Lee D, Hawkes E. Wong KSQ, et al. J Natl Cancer Inst. 2025 Nov 1;117(11):2240-2248. doi: 10.1093/jnci/djaf174. J Natl Cancer Inst. 2025. PMID: 40637697